Skip to content
HowShorted

Viking Therapeutics, Inc. short interest in 2018

In 2018, Viking Therapeutics, Inc.'s disclosed short interest ran from 6.90% of shares outstanding on 12 Jan 2018 to 33.31% on 31 Dec 2018, a change of +26.41 percentage points. The year's high was 33.31% on 31 Dec 2018 and its low 5.19% on 15 May 2018, averaging 17.29% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.44 days on 14 Dec 2018. Full history: Viking Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Viking Therapeutics, Inc. in 2018

2018 in figures

Start of year
6.90% (12 Jan 2018)
End of year
33.31% (31 Dec 2018)
Change
+26.41 pp
High
33.31% (31 Dec 2018)
Low
5.19% (15 May 2018)
Average
17.29%
Highest days to cover
9.44 (14 Dec 2018)
SEC filings marked
8

Every report in 2018

Viking Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20186.90%2.36
31 Jan 20186.22%1.81
15 Feb 20188.52%1.00
28 Feb 20187.76%1.28
15 Mar 20189.91%2.3010-K filed, results (8-K)
29 Mar 20188.49%2.86
13 Apr 201810.26%4.17
30 Apr 20185.72%3.27
15 May 20185.19%3.7910-Q filed, results (8-K)
31 May 20186.58%1.00
15 Jun 201812.08%1.00
29 Jun 201819.04%2.71
13 Jul 201821.12%5.91
31 Jul 201817.62%5.40
15 Aug 201817.30%7.5510-Q filed, results (8-K)
31 Aug 201816.36%4.28
14 Sep 201817.23%5.19
28 Sep 201825.32%1.27
15 Oct 201832.66%4.81
31 Oct 201831.09%7.60
15 Nov 201831.61%5.0410-Q filed, results (8-K)
30 Nov 201832.91%7.57
14 Dec 201831.88%9.44
31 Dec 201833.31%7.21

See also: Viking Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.